Corline Biomedical AB (STO:CLBIO)

Corline Biomedical AB Statistics

Total Valuation

STO:CLBIO has a market cap or net worth of SEK 465.33 million. The enterprise value is 457.00 million.

Market Cap	465.33M
Enterprise Value	457.00M

Important Dates

The next estimated earnings date is Friday, November 7, 2025.

Earnings Date	Nov 7, 2025
Ex-Dividend Date	n/a

Share Statistics

STO:CLBIO has 24.49 million shares outstanding. The number of shares has increased by 8.47% in one year.

Current Share Class	24.49M
Shares Outstanding	24.49M
Shares Change (YoY)	+8.47%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	47.90%
Owned by Institutions (%)	13.67%
Float	8.50M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	46.42
PB Ratio	5.77
P/TBV Ratio	5.77
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-19.46
EV / Sales	45.59
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-24.05

Financial Position

The company has a current ratio of 2.09

Current Ratio	2.09
Quick Ratio	1.98
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-462.60

Financial Efficiency

Return on equity (ROE) is -27.94% and return on invested capital (ROIC) is -10.32%.

Return on Equity (ROE)	-27.94%
Return on Assets (ROA)	-9.26%
Return on Invested Capital (ROIC)	-10.32%
Return on Capital Employed (ROCE)	-17.22%
Revenue Per Employee	771,077
Profits Per Employee	-1.81M
Employee Count	13
Asset Turnover	0.11
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +111.11% in the last 52 weeks. The beta is 0.27, so STO:CLBIO's price volatility has been lower than the market average.

Beta (5Y)	0.27
52-Week Price Change	+111.11%
50-Day Moving Average	14.66
200-Day Moving Average	11.44
Relative Strength Index (RSI)	63.54
Average Volume (20 Days)	117,061

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, STO:CLBIO had revenue of SEK 10.02 million and -23.49 million in losses. Loss per share was -1.01.

Revenue	10.02M
Gross Profit	6.89M
Operating Income	-13.88M
Pretax Income	-23.49M
Net Income	-23.49M
EBITDA	-13.78M
EBIT	-13.88M
Loss Per Share	-1.01

Balance Sheet

The company has 8.32 million in cash and n/a in debt, giving a net cash position of 8.32 million or 0.34 per share.

Cash & Cash Equivalents	8.32M
Total Debt	n/a
Net Cash	8.32M
Net Cash Per Share	0.34
Equity (Book Value)	80.59M
Book Value Per Share	3.29
Working Capital	6.30M

Cash Flow

In the last 12 months, operating cash flow was -18.98 million and capital expenditures -28,000, giving a free cash flow of -19.01 million.

Operating Cash Flow	-18.98M
Capital Expenditures	-28,000
Free Cash Flow	-19.01M
FCF Per Share	-0.78

Margins

Gross margin is 68.70%, with operating and profit margins of -138.45% and -234.29%.

Gross Margin	68.70%
Operating Margin	-138.45%
Pretax Margin	-234.29%
Profit Margin	-234.29%
EBITDA Margin	-137.43%
EBIT Margin	-138.45%
FCF Margin	n/a

Dividends & Yields

STO:CLBIO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-8.47%
Shareholder Yield	n/a
Earnings Yield	-5.05%
FCF Yield	-4.08%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

STO:CLBIO has an Altman Z-Score of 20.8 and a Piotroski F-Score of 2.

Altman Z-Score	20.8
Piotroski F-Score	2